

Tiago A Mestre

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5733218/publications.pdf>

Version: 2024-02-01

104
papers

2,593
citations

212478

28
h-index

263392

45
g-index

110
all docs

110
docs citations

110
times ranked

3633
citing authors

#	ARTICLE	IF	CITATIONS
1	A roadmap for implementation of patient-centered digital outcome measures in Parkinson's disease obtained using mobile health technologies. <i>Movement Disorders</i> , 2019, 34, 657-663.	2.2	213
2	Data Analytics from Enroll- <i>HD</i> , a Global Clinical Research Platform for Huntington's Disease. <i>Movement Disorders Clinical Practice</i> , 2017, 4, 212-224.	0.8	137
3	MDS evidence-based review of treatments for essential tremor. <i>Movement Disorders</i> , 2019, 34, 950-958.	2.2	108
4	Motor and nonmotor heterogeneity of <i>LRRK2</i> -related and idiopathic Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1192-1202.	2.2	102
5	The long-term outcome of orthostatic tremor. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309942.	0.9	100
6	Therapeutic interventions for symptomatic treatment in Huntington's disease. <i>The Cochrane Library</i> , 2009, , CD006456.	1.5	91
7	Canadian guideline for Parkinson disease. <i>Cmaj</i> , 2019, 191, E989-E1004.	0.9	90
8	Vision-based assessment of parkinsonism and levodopa-induced dyskinesia with pose estimation. <i>Journal of NeuroEngineering and Rehabilitation</i> , 2018, 15, 97.	2.4	71
9	Subthalamic nucleus deep brain stimulation for early motor complications in Parkinson's disease—the EARLYSTIM trial: Early is not always better. <i>Movement Disorders</i> , 2014, 29, 1751-1756.	2.2	68
10	Factors influencing the outcome of deep brain stimulation: Placebo, nocebo, lessebo, and lesion effects. <i>Movement Disorders</i> , 2016, 31, 290-298.	2.2	68
11	Transducer-based evaluation of tremor. <i>Movement Disorders</i> , 2016, 31, 1327-1336.	2.2	64
12	Reproducibility of data-driven Parkinson's disease subtypes for clinical research. <i>Parkinsonism and Related Disorders</i> , 2018, 56, 102-106.	1.1	63
13	Parkinson's Disease Subtypes: Critical Appraisal and Recommendations. <i>Journal of Parkinson's Disease</i> , 2021, 11, 395-404.	1.5	56
14	5-Hydroxytryptamine 2A receptor antagonists as potential treatment for psychiatric disorders. <i>Expert Opinion on Investigational Drugs</i> , 2013, 22, 411-421.	1.9	53
15	Therapeutic interventions for disease progression in Huntington's disease. <i>The Cochrane Library</i> , 2009, , CD006455.	1.5	52
16	Fifteen Years of Clinical Trials in Huntington's Disease: A Very Low Clinical Drug Development Success Rate. <i>Journal of Huntington's Disease</i> , 2017, 6, 157-163.	0.9	50
17	Long-term double-blind unilateral pedunculopontine area stimulation in Parkinson's disease. <i>Movement Disorders</i> , 2016, 31, 1570-1574.	2.2	47
18	Placebo and nocebo responses in restless legs syndrome. <i>Neurology</i> , 2017, 88, 2216-2224.	1.5	46

#	ARTICLE	IF	CITATIONS
19	Another face of placebo: The lessebo effect in Parkinson disease. <i>Neurology</i> , 2014, 82, 1402-1409.	1.5	45
20	Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2016, 31, 1466-1478.	2.2	44
21	The Parkinson's disease eâ€diary: Developing a clinical and research tool for the digital age. <i>Movement Disorders</i> , 2019, 34, 676-681.	2.2	43
22	Restless Genital Syndrome in Parkinson Disease. <i>JAMA Neurology</i> , 2014, 71, 1559.	4.5	42
23	Therapy of Parkinson's Disease Subtypes. <i>Neurotherapeutics</i> , 2020, 17, 1366-1377.	2.1	42
24	Therapeutic Update on Huntington's Disease: Symptomatic Treatments and Emerging Disease-Modifying Therapies. <i>Neurotherapeutics</i> , 2020, 17, 1645-1659.	2.1	40
25	Rating scales for cognition in Huntington's disease: Critique and recommendations. <i>Movement Disorders</i> , 2018, 33, 187-195.	2.2	38
26	Gene Expression Differences in Peripheral Blood of Parkinsonâ€™s Disease Patients with Distinct Progression Profiles. <i>PLoS ONE</i> , 2016, 11, e0157852.	1.1	36
27	Development of the Integrated Parkinsonâ€™s Care Network (IPCN): using co-design to plan collaborative care for people with Parkinsonâ€™s disease. <i>Quality of Life Research</i> , 2019, 28, 1355-1364.	1.5	33
28	Technology-Enabled Care: Integrating Multidisciplinary Care in Parkinson's Disease Through Digital Technology. <i>Frontiers in Neurology</i> , 2020, 11, 575975.	1.1	32
29	Diagnosis and treatment of impulse control disorders in patients with movement disorders. <i>Therapeutic Advances in Neurological Disorders</i> , 2013, 6, 175-188.	1.5	29
30	Are genetic and idiopathic forms of Parkinson's disease the same disease?. <i>Journal of Neurochemistry</i> , 2020, 152, 515-522.	2.1	28
31	Measurement Instruments to Assess Functional Mobility in Parkinson's Disease: A Systematic Review. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 129-139.	0.8	28
32	Rating Scales for Motor Symptoms and Signs in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 111-117.	0.8	27
33	Moving towards home-based community-centred integrated care in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2020, 78, 21-26.	1.1	27
34	What motivates Parkinsonâ€™s disease patients to enter clinical trials?. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 667-671.	1.1	26
35	What is a clinically important change in the Unified Dyskinesia Rating Scale in Parkinson's disease?. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 1349-1354.	1.1	24
36	Quality of Life in Huntington's Disease: Critique and Recommendations for Measures Assessing Patient Healthâ€™Related Quality of Life and Caregiver Quality of Life. <i>Movement Disorders</i> , 2018, 33, 742-749.	2.2	23

#	ARTICLE	IF	CITATIONS
37	Uptake of telehealth in Parkinson's disease clinical care and research during the COVID-19 pandemic. <i>Parkinsonism and Related Disorders</i> , 2021, 86, 97-100.	1.1	23
38	Rating Scales and Performance-based Measures for Assessment of Functional Ability in Huntington's Disease: Critique and Recommendations. <i>Movement Disorders Clinical Practice</i> , 2018, 5, 361-372.	0.8	22
39	Automated assessment of levodopa-induced dyskinesia: Evaluating the responsiveness of video-based features. <i>Parkinsonism and Related Disorders</i> , 2018, 53, 42-45.	1.1	22
40	A novel KCNA1 mutation in a family with episodic ataxia and malignant hyperthermia. <i>Neurogenetics</i> , 2016, 17, 245-249.	0.7	21
41	Placebo and nocebo responses in other movement disorders besides Parkinson's disease: How much do we know?. <i>Movement Disorders</i> , 2018, 33, 1228-1235.	2.2	21
42	Espresso Coffee for the Treatment of Somnolence in Parkinson's Disease: Results of n-of-1 Trials. <i>Frontiers in Neurology</i> , 2016, 7, 27.	1.1	19
43	Huntington Disease: Linking Pathogenesis to the Development of Experimental Therapeutics. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 18.	2.0	19
44	An MDS Evidence-Based Review on Treatments for Huntington's Disease. <i>Movement Disorders</i> , 2022, 37, 25-35.	2.2	19
45	Investigating Voice as a Biomarker for Leucine-Rich Repeat Kinase 2-Associated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2018, 8, 503-510.	1.5	18
46	Nocebo response in Parkinson's disease: A systematic review and meta-analysis. <i>Parkinsonism and Related Disorders</i> , 2019, 65, 13-19.	1.1	18
47	Moving towards Integrated and Personalized Care in Parkinson's Disease: A Framework Proposal for Training Parkinson Nurses. <i>Journal of Personalized Medicine</i> , 2021, 11, 623.	1.1	18
48	Bilateral pallidal stimulation for sargoglycan epsilon negative myoclonus. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 915-918.	1.1	17
49	Modelling idiopathic Parkinson disease as a complex illness can inform incidence rate in healthy adults: the R-EDIGT score. <i>European Journal of Neuroscience</i> , 2017, 45, 175-191.	1.2	17
50	The Disease Modification Conundrum in Parkinson's Disease: Failures and Hopes. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 810860.	1.7	17
51	Can Isolated Enlarged Virchow-Robin Spaces Influence the Clinical Manifestations of Parkinson's Disease?. <i>Movement Disorders Clinical Practice</i> , 2014, 1, 67-69.	0.8	14
52	Recent advances in the therapeutic development for Huntington disease. <i>Parkinsonism and Related Disorders</i> , 2019, 59, 125-130.	1.1	13
53	Pilot Evaluation of a Pragmatic Network for Integrated Care and Self-Management in Parkinson's Disease. <i>Movement Disorders</i> , 2021, 36, 398-406.	2.2	13
54	Remote Evaluation of Parkinson's Disease Using a Conventional Webcam and Artificial Intelligence. <i>Frontiers in Neurology</i> , 2021, 12, 742654.	1.1	13

#	ARTICLE	IF	CITATIONS
55	Clustering of motor and nonmotor traits in leucineâ€rich repeat kinase 2 G2019S Parkinson's disease nonparkinsonian relatives: A multicenter family study. <i>Movement Disorders</i> , 2018, 33, 960-965.	2.2	12
56	Drooling rating scales in Parkinson's disease: A systematic review. <i>Parkinsonism and Related Disorders</i> , 2021, 91, 173-180.	1.1	12
57	Co-designing a digital companion with people living with Parkinson's to support self-care in a personalized way: The eCARE-PD Study. <i>Digital Health</i> , 2022, 8, 205520762210816.	0.9	11
58	Small and Large Magnetic Resonance Imagingâ€Visible Perivascular Spaces in the Basal Ganglia of Parkinson's Disease Patients. <i>Movement Disorders</i> , 2022, 37, 1304-1309.	2.2	11
59	Actigraphy Detects Greater Intra-Individual Variability During Gait in Non-Manifesting LRRK2 Mutation Carriers. <i>Journal of Parkinson's Disease</i> , 2018, 8, 131-139.	1.5	10
60	Glycopyrrolate Improves Disability From Sialorrhea in Parkinson's Disease: A <scp>12â€Week</scp> Controlled Trial. <i>Movement Disorders</i> , 2020, 35, 2319-2323.	2.2	10
61	Vitamins and Infusion of Levodopa-Carbidopa Intestinal Gel. <i>Canadian Journal of Neurological Sciences</i> , 2022, 49, 19-28.	0.3	8
62	Strong nocebo effect in amyotrophic lateral sclerosis trials might mask conclusions. <i>Lancet Neurology</i> , The, 2018, 17, 842.	4.9	7
63	Nocebo and lessebo effects. <i>International Review of Neurobiology</i> , 2020, 153, 121-146.	0.9	7
64	The Integrated Parkinsonâ€™s disease Care Network (IPCN): Qualitative evaluation of a new approach to care for Parkinsonâ€™s disease. <i>Patient Education and Counseling</i> , 2021, 104, 136-142.	1.0	7
65	Epidemiology and economic burden of Huntingtonâ€™s disease: a Canadian provincial public health system perspective. <i>Journal of Medical Economics</i> , 2022, 25, 212-219.	1.0	7
66	Current Use of Domperidone and Co-prescribing of Medications that Increase Its Arrhythmogenic Potential Among Older Adults: A Population-Based Cohort Study in Ontario, Canada. <i>Drugs and Aging</i> , 2014, 31, 805-813.	1.3	6
67	Placebos in clinical trials: unravelling a complex phenomenon. <i>Lancet Neurology</i> , The, 2017, 16, 28-29.	4.9	6
68	Reluctance to start medication for Parkinson's disease: A mutual misunderstanding by patients and physicians. <i>Parkinsonism and Related Disorders</i> , 2014, 20, 608-612.	1.1	5
69	Impact of New Technologies in a Stroke Presentation: A Case of Dystextia and Dystypia. <i>Canadian Journal of Neurological Sciences</i> , 2017, 44, 458-460.	0.3	5
70	The Role of Architecture and Design in the Management of Parkinsonâ€™s Disease: A Systematic Review. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1301-1314.	1.5	5
71	Toward <scp>eâ€™Scales</scp>: Digital Administration of the International Parkinson and Movement Disorder Society Rating Scales. <i>Movement Disorders Clinical Practice</i> , 2021, 8, 208-214.	0.8	5
72	Designing socially acceptable mHealth technologies for Parkinson's disease self-management. <i>Finnish Journal of EHealth and EWelfare</i> , 2020, 12, 163-178.	0.0	5

#	ARTICLE	IF	CITATIONS
73	Are placebo pills presented as experimental treatment a true placebo?. Pain, 2017, 158, 535-535.	2.0	4
74	Expectations of Benefit in a Trial of a Candidate Disease—Modifying Treatment for Parkinson Disease. Movement Disorders, 2021, 36, 1964-1967.	2.2	4
75	Harnessing the power of placebos in movement disorders: Insights from Parkinson's disease in clinical research and practice. Movement Disorders, 2018, 33, 1195-1203.	2.2	3
76	The dawn of a new era for neurodegenerative disorders: Huntington's disease leading the way. Movement Disorders, 2019, 34, 1301-1302.	2.2	3
77	Synuclein Meeting 2019: where we are and where we need to go. Journal of Neurochemistry, 2019, 150, 462-466.	2.1	3
78	Thyrotoxicosis Resulting in Unilateral Upper Limb Chorea and Ballismus. Canadian Journal of Neurological Sciences, 2021, , 1-2.	0.3	3
79	Validation of biomarkers in Huntington disease to support the development of disease-modifying therapies: A systematic review and critical appraisal scheme. Parkinsonism and Related Disorders, 2021, 93, 89-96.	1.1	3
80	Resolving Missing Data from the Movement Disorder Society Unified Parkinson's Disease Rating Scale: Implications for Telemedicine. Movement Disorders, 2022, 37, 1749-1755.	2.2	3
81	The Role of Parkinson Nurses for Personalizing Care in Parkinson's Disease: A Systematic Review and Meta-Analysis. Journal of Parkinson's Disease, 2022, 12, 1807-1831.	1.5	3
82	The placebo response in Parkinson's disease and other movement disorders. Movement Disorders, 2018, 33, 1193-1194.	2.2	2
83	Patient-centred management of Parkinson's disease. Lancet Neurology, The, 2020, 19, 887-888.	4.9	2
84	Coping Styles in Patients with Parkinson's Disease: Consideration in the Co-Designing of Integrated Care Concepts. Journal of Personalized Medicine, 2022, 12, 921.	1.1	2
85	A rare cause of orofacial dyskinesias. Parkinsonism and Related Disorders, 2018, 50, 122-123.	1.1	1
86	Intermittent undulating tongue as an involuntary movement in early amyotrophic lateral sclerosis. Parkinsonism and Related Disorders, 2019, 67, 1-2.	1.1	1
87	F01—Development of the huntington's disease integrated staging system (HD-ISS). , 2021, , .		1
88	Evaluation of the Impact of Integrated Care and Self-Management After Deep Brain Stimulation in Parkinson's Disease. Journal of Parkinson's Disease, 2022, 12, 1279-1284.	1.5	1
89	Disease Burden of Huntington's Disease (HD) on People Living with HD and Care Partners in Canada. Journal of Huntington's Disease, 2022, , 1-15.	0.9	1
90	Therapeutic interventions for sleep disorders in Parkinson's disease. The Cochrane Library, 0, , .	1.5	0

#	ARTICLE	IF	CITATIONS
91	Therapeutic interventions for daytime somnolence in Parkinson's disease. The Cochrane Library, 2007, , .	1.5	0
92	Emerging targets and other stimulation-related procedures in the management of Parkinson's disease. , 0, , 216-230.		0
93	A12...How does Enroll-HD expedite/facilitate the conduct of clinical trials?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A4.1-A4.	0.9	0
94	I31...Enroll-HD: current status. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A69.2-A70.	0.9	0
95	I30...Enroll-HD: a global clinical research platform for huntington... disease. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A69.1-A69.	0.9	0
96	Response to letter by Saenz...Farret et al. on ...Rating scales for behavioral symptoms in Huntington's disease: Critique and recommendations... Movement Disorders, 2017, 32, 482-482.	2.2	0
97	PO104...Placebo and nocebo responses in rls: a meta-analysis. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, A39.1-A39.	0.9	0
98	Introducing the new ...Movement Disorders Rounds... Parkinsonism and Related Disorders, 2018, 55, 1.	1.1	0
99	Assessing and managing Parkinson's disease from home: A 21st century vision closer to reality. Movement Disorders, 2018, 33, 1407-1407.	2.2	0
100	Reply to ...Studying reproducibility of data-driven Parkinson's disease subtypes... Parkinsonism and Related Disorders, 2019, 66, 245-246.	1.1	0
101	An 8-year-old boy with ataxia and abnormal movements. Paediatrics and Child Health, 2019, 24, 297-298.	0.3	0
102	Huntington... Disease and Hypertension: Sorting Out Mixed Messages. Movement Disorders, 2020, 35, 915-917.	2.2	0
103	Return on Investment Analysis for the Integrated Parkinson... Care Network: Lesson Learned from a Pilot Study. Journal of Parkinson's Disease, 2021, 11, 1-7.	1.5	0
104	Using Big Data in Movement Disorders: Disease States and Progression in Huntington's Disease. Movement Disorders, 2022, 37, 441-443.	2.2	0